A case of tetrabenazine‐induced neuroleptic malignant syndrome after prolonged treatment

Petzinger, Giselle M.; Bressman, Susan

doi:10.1002/mds.870120219

Cited by 39 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could argue for a more complex pathogenesis of the hyperthermia seen in our patient than simple dopamine depletion and blockade by tetrabenazine alone. This could also explain the clinical differences observed here in comparison with the classical neuroleptic malignant syndrome (absence of muscle rigidity, absence of cardiac and autonomic instability, abrupt response to treatment with sodium dantrolene and bromocriptine) as postulated by other authors [4]. The significant role of tetrabenazine can nevertheless be inferred from the pharmacokinetic properties of the native drug and its active hydroxy metabolite (half-life 6.5 vs 10 h) [10].…”

Section: Discussionmentioning

confidence: 51%

“…In conclusion, we suggest that tetrabenazine should be added to the list of drugs inducing neuroleptic malignant syndrome-like hyperthermia, either when used alone [3,4] or in combination with alphamethylparatyrosine (a dopamine synthesis inhibitor used in the treatment of movement disorders) [1], neuroleptics [2], or serotoninergic antidepressants.…”

Section: Discussionmentioning

confidence: 99%

“…We also reviewed reference lists of relevant articles cited. We only found four descriptions of tetrabenazine-induced hyperthermia, three in patients with Huntington's disease [1][2][3] and one in a patient with neuroleptic tardive dystonia [4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia

et al. 1998

View full text Add to dashboard Cite

We recently observed a 45-year-old patient with a history of psychiatric illness who presented with severe hyperthermia (rectal temperature above 41 degrees C) with intense rhabdomyolysis and liver cytolysis during tetrabenazine therapy for neuroleptic tardive dyskinesia. In addition to tetrabenazine, this patient took lorazepam and two antidepressant drugs: clomipramine, a potent serotonin-reuptake inhibitor, and mianserin. Hyperthermia responded to parenteral sodium dantrolene and oral bromocriptine administration. The significant role of tetrabenazine (a central nervous system dopamine-depleting drug) and the contribution of antidepressants to the mechanism of this neuroleptic malignant syndrome - like hyperthermia are discussed.

show abstract

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Children may tolerate higher doses of tetrabenazine than adults 34 . Tetrabenazine does not cause tardive phenomena but dopamine-depleting agents can cause neuroleptic malignant syndrome even after years of use 35 .…”

Section: Tic-suppressing Drugsmentioning

confidence: 99%

Epidemiology of Tics

Ortiz¹,

Cornejo²,

Blazicevich³

2012

Epidemiology Insights

View full text Add to dashboard Cite

“…Tetrabenazine is effective in controlling involuntary movements in patients with HD by inhibiting dopaminergic neurons with relative safety (at a daily dose of 12.5-100 mg) (2). Neuroleptic malignant syndrome (NMS) is a rare adverse event of neuroleptic drugs and extremely rare in patients treated with tetrabenazine (3)(4)(5)(6). We herein present the case of a Japanese patient with HD presenting with NMS induced by tetrabenazine combined with tiapride.…”

Section: Introductionmentioning

confidence: 98%

Neuroleptic Malignant Syndrome Induced by Combination Therapy with Tetrabenazine and Tiapride in a Japanese Patient with Huntington's Disease at the Terminal Stage of Recurrent Breast Cancer

et al. 2014

View full text Add to dashboard Cite

We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease. The patient had been treated with tiapride or tetrabenazine alone without any adverse effects before the administration of the combination therapy. She also had advanced breast cancer when the combination therapy was initiated. To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other neuroleptic drugs, particularly in patients with a worsening general condition.

show abstract

A case of tetrabenazine‐induced neuroleptic malignant syndrome after prolonged treatment

Cited by 39 publications

References 21 publications

Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia

Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia

Epidemiology of Tics

Neuroleptic Malignant Syndrome Induced by Combination Therapy with Tetrabenazine and Tiapride in a Japanese Patient with Huntington's Disease at the Terminal Stage of Recurrent Breast Cancer

Contact Info

Product

Resources

About